BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30967505)

  • 1. Histone H3 tail binds a unique sensing pocket in EZH2 to activate the PRC2 methyltransferase.
    Jani KS; Jain SU; Ge EJ; Diehl KL; Lundgren SM; Müller MM; Lewis PW; Muir TW
    Proc Natl Acad Sci U S A; 2019 Apr; 116(17):8295-8300. PubMed ID: 30967505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of histone methylation by automethylation of PRC2.
    Wang X; Long Y; Paucek RD; Gooding AR; Lee T; Burdorf RM; Cech TR
    Genes Dev; 2019 Oct; 33(19-20):1416-1427. PubMed ID: 31488576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for PRC2 decoding of active histone methylation marks H3K36me2/3.
    Finogenova K; Bonnet J; Poepsel S; Schäfer IB; Finkl K; Schmid K; Litz C; Strauss M; Benda C; Müller J
    Elife; 2020 Nov; 9():. PubMed ID: 33211010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2.
    Lee CH; Holder M; Grau D; Saldaña-Meyer R; Yu JR; Ganai RA; Zhang J; Wang M; LeRoy G; Dobenecker MW; Reinberg D; Armache KJ
    Mol Cell; 2018 May; 70(3):435-448.e5. PubMed ID: 29681498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
    Yap DB; Chu J; Berg T; Schapira M; Cheng SW; Moradian A; Morin RD; Mungall AJ; Meissner B; Boyle M; Marquez VE; Marra MA; Gascoyne RD; Humphries RK; Arrowsmith CH; Morin GB; Aparicio SA
    Blood; 2011 Feb; 117(8):2451-9. PubMed ID: 21190999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
    McCabe MT; Graves AP; Ganji G; Diaz E; Halsey WS; Jiang Y; Smitheman KN; Ott HM; Pappalardi MB; Allen KE; Chen SB; Della Pietra A; Dul E; Hughes AM; Gilbert SA; Thrall SH; Tummino PJ; Kruger RG; Brandt M; Schwartz B; Creasy CL
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2989-94. PubMed ID: 22323599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H3K36 methylation antagonizes PRC2-mediated H3K27 methylation.
    Yuan W; Xu M; Huang C; Liu N; Chen S; Zhu B
    J Biol Chem; 2011 Mar; 286(10):7983-7989. PubMed ID: 21239496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of EZH1 and EZH2 in development and cancer.
    Lee SH; Li Y; Kim H; Eum S; Park K; Lee CH
    BMB Rep; 2022 Dec; 55(12):595-601. PubMed ID: 36476271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.
    Shen X; Liu Y; Hsu YJ; Fujiwara Y; Kim J; Mao X; Yuan GC; Orkin SH
    Mol Cell; 2008 Nov; 32(4):491-502. PubMed ID: 19026780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.
    Sneeringer CJ; Scott MP; Kuntz KW; Knutson SK; Pollock RM; Richon VM; Copeland RA
    Proc Natl Acad Sci U S A; 2010 Dec; 107(49):20980-5. PubMed ID: 21078963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
    Romero P; Richart L; Aflaki S; Petitalot A; Burton M; Michaud A; Masliah-Planchon J; Kuhnowski F; Le Cam S; Baliñas-Gavira C; Méaudre C; Luscan A; Hamza A; Legoix P; Vincent-Salomon A; Wassef M; Holoch D; Margueron R
    Nat Commun; 2024 Apr; 15(1):3452. PubMed ID: 38658543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycomb repressive complex 2 in an autoinhibited state.
    Bratkowski M; Yang X; Liu X
    J Biol Chem; 2017 Aug; 292(32):13323-13332. PubMed ID: 28607149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycomb Repressive Complex 2 in Oncology.
    Guo Y; Yu Y; Wang GG
    Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.
    Justin N; Zhang Y; Tarricone C; Martin SR; Chen S; Underwood E; De Marco V; Haire LF; Walker PA; Reinberg D; Wilson JR; Gamblin SJ
    Nat Commun; 2016 Apr; 7():11316. PubMed ID: 27121947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2).
    Xu C; Bian C; Yang W; Galka M; Ouyang H; Chen C; Qiu W; Liu H; Jones AE; MacKenzie F; Pan P; Li SS; Wang H; Min J
    Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19266-71. PubMed ID: 20974918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
    Mu W; Starmer J; Yee D; Magnuson T
    Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
    Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
    Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The deletion of the protein phosphatase 1 regulator NIPP1 in testis causes hyperphosphorylation and degradation of the histone methyltransferase EZH2.
    Ferreira M; Verbinnen I; Fardilha M; Van Eynde A; Bollen M
    J Biol Chem; 2018 Nov; 293(47):18031-18039. PubMed ID: 30305391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.